Biological and pharmacological roles of m6A modifications in cancer drug resistance

Table 1 The role of m⁶A modification in the cancer biological functions

Type	m⁶A regulator	Activity	Ref
m⁶A writer	METTL3	catalyzes methylation reaction	[14]
	METTL14	assists METTL3 to recognize the subtract	[15]
	METTL16	catalyzes m⁶A modification	[16]
	WTAP	promotes METTL3-METTL14 heterodimer localization into nuclear speckles	[17]
	KIAA1429	directs the methyltransferase components to specific RNA region	[18]
	VIRMA	recruits the methyltransferase core components and associates with polyadenylation cleavage factors CPSF5 and CPSF6	[19]
	RBM15	binds the m⁶A complex and recruits it to a special RNA site	[20]
	ZC3H13	bridges WTAP to the mRNA-binding factor Nito	[21]
m⁶A eraser	FTO	reduces methylated bases	[22]
	ALKBH5	downregulates m⁶A modification level	[23]
m⁶A reader	YTHDC1	accelerates mRNA nuclear transport and alternative splicing	[24]
	YTHDC2	promotes the target RNA translation	[25]
	YTHDF1	enhances the translation of mRNA	[26]
	YTHDF2	increases mRNA degradation	[27]
	YTHDF3	mediates the translation or degradation	[28]
	HNRNPA2B1	promotes primary microRNA processing and mediates nuclear accumulation	[29]
	HNRNPC	mediates mRNA splicing and maturity	[30]
	IGF2BP1/2/3	enhances mRNA stability	[31]
	eIF3	enhances mRNA translation	[32]

ISSN: 1476-4598